This study aimed to evaluate the efficacy and safety of continuing versus stopping aspirin [acetylsalicylic acid (ASA)] preoperatively in patients undergoing coronary artery bypass graft surgery. MEDLINE, EMBASE, CENTRAL/Cochrane Controlled Trials Register (CCTR), ClinicalTrials.gov, Scientific Electronic Library Online (SciELO), Literatura Latino Americana em Ciências da Sa ude (LILACS), Google Scholar and reference lists of relevant articles were searched for randomized controlled trials that reported efficacy outcomes of myocardial infarction and mortality, and safety outcomes of blood loss, packed red blood cell transfusion and surgical re-exploration were compared between groups. Fourteen studies fulfilled our eligibility criteria and included a total of 4499 patients (2329 for 'continuing ASA' and 2170 for 'stopping ASA'). In the pooled analysis, continuing aspirin therapy did not reduce the risk of myocardial infarction [risk ratio 0.834, 95% confidence interval (CI) 0.688-1.010; P = 0.063] or operative mortality (risk ratio 1.384, 95% CI 0.727-2.636; P = 0.323). Preoperative ASA increased postoperative chest tube drainage (mean difference 143 ml, 95% CI 39-248 ml; P = 0.007) and packed red blood cell transfusion (mean difference 142 ml, 95% CI 55-228; P = 0.001) but did not increase the risk of surgical re-exploration (risk ratio 1.316, 95% CI 0.910-1.905; P = 0.145). This meta-analysis found no statistically significant difference regarding the risk of operative mortality and myocardial infarction between the 'continuing ASA' and 'stopping ASA' strategies. On the other hand, the mean volume of blood loss and packed red blood cell transfusion was higher in the 'continuing ASA' group, but this finding did not translate into higher risk of reoperation for bleeding.
INTRODUCTION

Rationale
It is unclear whether aspirin [acetylsalicylic acid (ASA)] should be continued or stopped in patients undergoing coronary artery bypass graft (CABG) surgery [1] . Conflicting guidelines from expert organizations highlight the scarcity of data from large clinical trials and the lack of reliable recommendations [2] [3] [4] [5] [6] .
Therefore, it is necessary to review the current state of published medical data with regard to this subject.
Objectives
This analysis was planned in accordance with the current guidelines for performing comprehensive systematic reviews and meta-analysis with meta-regression, including the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) [7] guidelines for randomized controlled trials. We aimed to determine whether preoperative ASA reduces the risk of myocardial infarction (MI) and death, potentially outweighing increased bleeding, packed red blood cell (PRBC) transfusion and surgical re-exploration. group receiving either placebo or no ASA; (iv) outcomes studied included any of the following: primary outcomes-death, postoperative MI, reoperation for haemorrhage and secondary outcomes-and postoperative blood loss as assessed by chest drainage and volume of PRBC received in the postoperative period and (v) studies were randomized controlled trials.
Information sources
The following databases were used (until December 2016): MEDLINE, EMBASE, CENTRAL/Cochrane Controlled Trials Register (CCTR), ClinicalTrials.gov, Scientific Electronic Library Online (SciELO), Literatura Latino Americana em Ciências da Sa ude (LILACS), Google Scholar and reference lists of relevant articles.
Search
We conducted the search with Medical Subject Headings (MeSH) terms ('aspirin' OR 'acetylsalicylic acid' OR 'acid, acetylsalicylic' OR '2-acetyloxybenzoic acid' OR 'acylpyrin' OR 'aloxiprimum' OR 'colfarit' OR 'dispril' OR 'easprin' OR 'ecotrin' OR 'endosprin' OR 'magnecyl' OR 'micristin' OR 'polopirin' OR 'polopiryna' OR 'solprin' OR 'solupsan' OR 'zorprin' OR 'acetysal') AND ('coronary artery bypass graft' OR 'coronary artery bypass grafting' OR 'coronary artery bypass surgery' OR 'coronary bypass surgery' OR 'coronary artery bypass graft surgery' OR 'coronary artery bypass' OR 'coronary bypass' OR 'coronary artery bypass, off-pump' OR 'coronary artery bypass, beating heart' OR 'off-pump coronary artery bypass' OR 'off-pump coronary artery bypass' OR 'beating heart coronary artery bypass').
Study selection
The following steps were taken: (i) identification of titles of records through databases searching, (ii) removal of duplicates, (iii) screening and selection of abstracts, (iv) assessment for eligibility through full-text articles and (v) final inclusion in study. One reviewer followed Steps i-iii. Two independent reviewers followed Step iv and selected studies. Inclusion or exclusion of studies was decided unanimously. When there was disagreement, a third reviewer made the final decision.
Data items
The crude end-points were operative mortality, MI and reoperation for haemorrhage, in terms of the number of events and the number of the total group in both arms. Other outcomes included blood loss (measured by chest tube drainage) and volume of packed red cell transfusion, in terms of the means (ml) and the standard deviation. For studies reporting interquartile ranges, the mean was estimated according to the formula [minimum + maximum + 2(median)]/4 and standard deviation was calculated using the formula (maximum -minimum)/6 [8] .
Data collection process
Two independent reviewers extracted the data. When there was disagreement regarding data, a third reviewer checked the data and made the final decision. From each study, we extracted patient characteristics, study design and outcomes.
Risk of bias in individual studies
Included studies were assessed for the following characteristics: sequence generation (randomization), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessors (detection bias), incomplete outcome data addressed (attrition bias) and selective outcome reporting (reporting bias). Taking these characteristics into account, the articles were classified into A (low risk of bias), B (moderate risk of bias) or C (high risk of bias). Two independent reviewers assessed the risk of bias. Agreement between the 2 reviewers was assessed with kappa statistics for full-text screening and rating of relevance and risk of bias. When there was disagreement regarding risk of bias, a third reviewer checked the data and made the final decision.
Summary measures
The principal summary measures were risk ratio (RR) with 95% confidence interval (CI) and P-values (considered statistically significant when P < 0.05) for operative mortality, postoperative MI and reoperation for haemorrhage. For postoperative blood loss and volume of packed red cells received in the postoperative period, difference in means with standard error and P-values (considered statistically significant when P < 0.05) were considered. The meta-analysis was completed with the software Comprehensive Meta-Analysis (version 2, Biostat, Inc., Englewood, NJ, USA).
Synthesis of results
Forest plots were generated for graphical presentations of clinical outcomes, and we performed the I 2 test and the v 2 test for the assessment of heterogeneity across the studies [9] . Inter-study heterogeneity was explored using the v 2 statistic, but the I 2 value was calculated to quantify the degree of heterogeneity across the studies that could not be attributable to chance alone. When the value of I 2 was more than 50%, significant statistical heterogeneity was considered to be present. Each study was summarized by the difference in means or RR, depending on the outcomes analysed. The RR and differences in means were combined across studies using a weighted DerSimonian-Laird random effects model [10] .
Risk of bias across studies
To assess the publication bias, a funnel plot was generated for each outcome, statistically assessed by the Begg and Mazumdar's test [11] and the Egger et al.'s test [12] .
Sensitivity analysis
Sensitivity analyses included assessment for evidence of a doseresponse effect of ASA, using a daily dose of 100 mg to stratify high-dose and low-dose regimens. This dose selection represented a decision based on current practices. Moreover, we investigated the influence of a single study on the overall effectby sequentially removing 1 study-to test the robustness of the main results, so that we could verify whether any study had an excessive influence on the overall results.
Meta-regression analysis
Meta-regression analyses were performed to determine whether the effects of aspirin were modulated by prespecified factors. Meta-regression graphs describe the effect of ASA on the outcome (plotted on the y-axis) as a function of a given factor (plotted as a mean or proportion of that factor on the x-axis).
The predetermined modulating factors to be examined were dose of ASA, age, gender, hypertension, diabetes, body mass index and renal failure.
RESULTS
Study selection
A total of 6008 citations were identified, of which 42 studies were potentially relevant and retrieved as full text. Fourteen publications [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] fulfilled our eligibility criteria. Inter-observer reliability of study relevance was excellent (kappa = 0.80). Agreement for decisions related to study validity was very good (kappa = 0.81). The search strategy is depicted in Fig. 1 .
Study characteristics
A total of 4499 patients (continuing aspirin: 2329 patients; stopping aspirin: 2170 patients) were included from studies published from 1985 to 2016. Only the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial was multicentric. Most studies consisted of patients whose mean or median age was approximately the sixth decade of life and who were mostly men. Antifibrinolytic use (aminocaproic acid, aprotinin, tranexamic acid; combined or isolated; in one or in both arms, etc.) was inconsistent across the studies (which precluded further analyses involving this possibly modulating factor). Postoperative ASA regimens varied substantially between studies and were inconsistently reported. ASA was continued in the postoperative period in 6 studies [15] [16] [17] [21] [22] [23] , and both arms in the ATACAS trial [13] received ASA within 24 h after surgery. Three studies [17, [22] [23] also reported first administration of ASA in the postoperative period within 6 h after the surgical procedure. The overall internal validity was considered moderate risk of bias ( Table 1) .
Synthesis of results
The RR for postoperative death in the 'continuing ASA' group compared with the 'stopping ASA' group in each study is reported in Fig. 2A . There was no evidence of heterogeneity of treatment effect among the studies for postoperative death. The overall RR (95% CI) of postoperative death showed no difference between continuing and stopping ASA (random effects model: RR 1.384, P = 0.830).
The RR for postoperative MI in the 'continuing ASA' group compared with the 'stopping ASA' group in each study is reported in Fig. 2B . There was no evidence of heterogeneity of treatment effect among the studies for postoperative MI. The overall RR (95% CI) of postoperative MI showed no difference between continuing and stopping ASA (random effects model: RR 0.834, P = 0.063).
The RR of reoperation for bleeding in the 'continuing ASA' group compared with the 'stopping ASA' group in each study is reported in Fig. 2C . There was no evidence of heterogeneity of treatment effect among the studies of reoperation for bleeding. The overall RR (95% CI) of reoperation for bleeding showed no difference between the continuing and the stopping ASA (random effects model: RR 1.316, P = 0.145).
The difference in means for blood loss (ml) according to the chest drainage in the 'continuing ASA' group compared with the 'stopping ASA' group in each study is reported in Fig. 3A . There was evidence of significant heterogeneity of treatment effect among the studies for this outcome. The overall difference in means of blood loss was significantly higher in the 'continuing ASA' group (random effects model: +143.892 ml, P = 0.007).
The difference in means for the volume of PRBC transfusion (ml) after CABG in the 'continuing ASA' group compared with the 'stopping ASA' group in each study is reported in Fig. 3B . There was evidence of significant heterogeneity of treatment effect among the studies for this outcome. The overall difference in means of the volume of PRBC transfusion was significantly higher in the 'continuing ASA' group (random effects model: +142.199 ml, P = 0.001).
Risk of bias across studies
Funnel plot analysis (Fig. 4) disclosed asymmetry around the axis for the treatment effect in the outcome 'reoperation for bleeding', identified by the Egger et al.'s test but not by the Begg and Mazumdar's test. Consequently, there was probably publication bias related to this outcome. Publication biases were not found in the other outcomes.
Sensitivity analysis
Sensitivity analyses performed by removing each single study from the meta-analysis to determine the influence of individual data sets to the pooled RR showed that the ATACAS trial caused a major change in direction/magnitude of statistical findings regarding the outcome 'reoperation for bleeding' (Fig. 5C ). When this study was removed from the analysis, a statistically significant difference in favour of stopping ASA arose, which means that this study actually had an excessive influence on the overall results with regard to this outcome, favouring excessively the 'continuing ASA' group when included.
Searching for evidence of a dose-response effect of ASA, we detected that there was a difference when patients used highdose and low-dose regimens (Fig. 6) .
Meta-regression analysis
Meta-regression coefficients were not statistically significant for the dose of ASA, age, gender, hypertension, diabetes, body mass index and renal failure, which means that none of these evaluated factors had any modulation influence on the final effect with regard to the analysed outcomes. 
DISCUSSION
Summary of evidence
To our knowledge, this is the largest meta-analysis of studies performed to date that provides incremental value by demonstrating that patients do not seem to benefit from continuing ASA when they undergo a CABG surgery, because we found no statistically significant differences regarding operative mortality and postoperative myocardial infarction (outcomes under no influence of heterogeneity of the effects). On the other hand, although continuing ASA increased the means of blood loss (which seemed to be dependent of the dose of aspirin according to the sensitivity analysis but not corroborated by the meta-regression analysis) and volume of PRBC transfusion (both outcomes under significant influence of heterogeneity of the effects), it did not increase the risk of reoperation for postoperative bleeding (outcome under no influence of heterogeneity of the effects).
Postoperative myocardial infarction (efficacy outcome) versus reoperation for bleeding (safety outcome)
Although we did not observe any statistically significant differences regarding the risks of postoperative MI and reoperation for haemorrhage, we did observe a tendency of more MI events in the 'stopping ASA' group and more events of reoperation for bleeding in the 'continuing ASA' group (both tendencies near to the statistical significance). The 'one-study-removed' sensitivity analysis revealed that, when the ATACAS trial is excluded from the analysis, a statistically significant difference arises with respect to the outcome 'reoperation for bleeding', which means that this trial had an extra influence on the results, actually favouring the 'continuing ASA' group in the pooled analysis. The 'one-studyremoved' sensitivity analysis also revealed that, when the ATACAS trial is excluded from the analysis, the risk reduction of postoperative MI is higher, but this finding was not statistically significant. We should bear in mind that the ATACAS trial had a higher than expected rate of MI in both the groups, and, with regard to our meta-analysis, it contributed to 86.7%. The ATACAS investigators speculate that this was the result of closer monitoring and increased troponin surveillance, i.e. higher detection rate. On the other hand, Kayse and Becker [27] put forward the idea that, because patients participating in the ATACAS study were given a 100-mg enteric-coated ASA 1-2 h prior to surgery, and based on the well-known pharmacokinetics of ASA, there is a high likelihood that there was not sufficient time to reach maximum serum concentration and maximum platelet inhibition prior to the start of the surgery. Therefore, once surgery begins and the patient is placed on cardiopulmonary bypass, local concentrations and related pharmacodynamics effects at coronary sites of plaque of newly placed bypass conduits would be quite low. One of the solutions to reduce the risk of postoperative bleeding could be tranexamic acid. Also the findings from the tranexamic acid arm of the very same ATACAS trial were published recently. Myles et al. [28] found no evidence that the use of tranexamic acid resulted in a higher risk of death or thrombotic complications than that with placebo among patients undergoing CABG. They also found that the tranexamic acid group had a lower risk of blood loss, blood transfusion and reoperation but a higher risk of postoperative seizures than the placebo group. Subgroup analyses of the primary outcome showed no significant interactions. The results were consistent among patients who were being treated with ASA and those who were not. Patients in the tranexamic acid group received 46% fewer units of blood products than those in the placebo group. There was no significant interaction between assignment to the tranexamic acid group and either assignment to the ASA group or previous exposure to ASA.
Another solution to avoid blood transfusions (by reducing transfusion requirements or reducing the decrease of haemoglobin levels or preventing anaemia) could be the preoperative iron administration, which has shown conflicting results. GarridoMart ın et al. [29] tested the clinical effectiveness of intravenous and oral iron supplementation in correcting anaemia, and its impact on blood transfusion requirements, in patients undergoing CABG. They carried out a double-blinded, randomized, placebocontrolled clinical trial with 3 parallel groups of patients. Group I (n = 54): intravenous iron (III)-hydroxide sucrose complex, 3 doses of 100 mg/24 h during pre-and postoperative hospitalization and 1 pill/24 h of oral placebo in the same period and during 1 month after discharge. Group II (n = 53): oral ferrous fumarate iron 1 pill/24 h pre-and postoperatively and during 1 month after discharge and intravenous placebo while hospitalized. Group III (n = 52): oral and intravenous placebo pre-and postoperatively, following the same protocol. Data were collected preoperatively, in theatre, at intensive care unit admission, before hospital discharge and 1 month later. Baseline clinical and demographic characteristics and surgical procedures were similar in the 3 groups; no inter-group differences were found in haemoglobin and haematocrit during the postoperative period and the intravenous iron group showed statistically significantly higher serum ferritin levels at hospital discharge and 1 month later compared with the other groups, but they did not observe statistical differences in blood transfusion requirements between the 3 groups. Another study, the PROTECT trial [30] , explored whether intravenous iron resulted in a better regeneration of haemoglobin levels and prevented anaemia compared with the placebo in preoperative non-anaemic patients undergoing cardiac surgery. The trial was a prospective, double-blinded, comparative, placebo-controlled trial of 60 non-anaemic patients undergoing cardiac surgery. The patients were randomized 1:1 to either 1000-mg intravenous iron administered perioperatively by infusion or placebo. The authors concluded that a single perioperative 1000-mg dose of intravenous iron significantly increased the haemoglobin level and prevented anaemia 4 weeks after surgery, with a short-term safety profile similar to placebo.
Putting this meta-analysis into perspective with the ESC/EACTS guidelines on myocardial revascularization
In spite of our findings, we would like to draw the readers' attention to the fact that the guidelines cited above state that the management of patients on dual antiplatelet therapy who are referred for surgical procedures depends on the level of emergency and the thrombotic and bleeding risk of the individual patient [31] . Most surgical procedures can be performed on dual antiplatelet therapy or at least on ASA alone with acceptable rates of bleeding. A multidisciplinary approach is required (cardiologist, anaesthesiologist, haematologist and surgeon) to determine the patient's risk (bleeding and thrombosis) and to choose the best strategy. In preparation for surgical procedures with high-to-very-high bleeding risk, it is recommended that clopidogrel be discontinued 5 days before surgery to reduce bleeding and the need for transfusion, while maintaining ASA throughout the perioperative period.
Risk of bias and limitations
There are inherent limitations with meta-analyses, including the use of cumulative data from summary estimates. Patient data were gathered from published data and not from individual patient follow-up. Access to individual patient data would have enabled us to conduct further subgroup analysis and propensity analysis to account for differences between the treatment groups. This meta-analysis included only data from randomized studies, which do not reflect the 'real world' but, on the other hand, are less limited by publication bias, treatment bias, confounders and a certain tendency to overestimate treatment effects observed in the observational studies, because patient selection alters outcome and thus make non-randomized studies less robust.
We must be careful when we bring together different studies in a systematic review. According to the Cochrane Handbook for Systematic Reviews of Interventions [32] , meta-analyses should only be considered when a group of studies is sufficiently homogeneous in terms of participants, interventions and outcomes to provide a meaningful summary. It is often appropriate to take a broader perspective in a meta-analysis than in a single clinical trial. A common analogy is that systematic reviews bring together apples and oranges and that combining these can yield a meaningless result. This is true if apples and oranges are of intrinsic interest on their own but may not be if they are used to contribute to a wider question about fruit. Any kind of variability among studies in a systematic review may be termed heterogeneity. In this case, it can be helpful to distinguish between different types of heterogeneity. Variability in the participants, interventions and outcomes studied may be described as clinical diversity (sometimes called clinical heterogeneity), and variability in study design and risk of bias may be described as methodological diversity (sometimes called methodological heterogeneity). In general, variability in the intervention effects being evaluated in the different studies is known as statistical heterogeneity and is a consequence of clinical or methodological diversity, or both, among the studies.
Furthermore, the present meta-analysis did not include all of the 14 studies for every outcome parameter investigated. Consequently, the number of the patients entering the metaanalysis varies greatly for each outcome, generally constituting only a fraction of the whole study population. There is a reason for this. When researchers perform meta-analyses, they are supposed to include only the studies containing any piece of information of interest predefined in the inclusion criteria. When they pool the data, they can include only those that have at least 1 event regarding a specific outcome. For example, when it comes to the outcome 'operative mortality' and we look at the studies, we realize that only 4 studies provided these data. Either the other studies did not provide any data regarding this outcome or they provided the data, but there was no event; in this case, no death in both arms, so we cannot include this study in the pooled analysis. When it comes to the outcome 'volume of RPBC transfusion', the ATACAS trial was not included because it did not provide this piece of information in the form of the amount of RPBC transfusion in millilitres but in the form of rates (in percentage) of RPBC transfusion. According to the Cochrane Handbook for Systematic Reviews of Interventions [30] , the standard practice in meta-analyses of odds ratios and RRs is to exclude studies from the meta-analyses where there are no events in both arms. This is because such studies do not provide any indication of either the direction or the magnitude of the relative treatment effect. Although it may be clear that events are very rare on both the experimental intervention and the control intervention, no information is provided as to which group is likely to have the higher risk or whether the risks are of the same or different orders of magnitude (when risks are very low, they are compatible with very large or very small ratio measures). Although one might be tempted to infer that the risk would be lowest in the group with the larger sample size (as the upper limit of the confidence interval would be lower), this is not justified as the sample size allocation was determined by the study investigators and is not a measure of the incidence of the event.
CONCLUSIONS
This meta-analysis found no statistical significant difference regarding the risk of operative mortality and MI between the 'continuing ASA' and 'stopping ASA' strategies. On the other hand, the mean volume of blood loss and PRBC transfusion was higher in the 'continuing ASA' group, but this finding did not translate into higher risk of reoperation for bleeding. Despite our findings, we agree with Kayse and Becker [27] when they say that we must always use sound judgement in patient care, prescribing ASA to patients who stand to benefit from its antithrombotic effects and those in whom the risk outweighs the benefit, for instance, in patients with acute coronary syndrome up to the time of surgery and in all patients undergoing CABG postoperatively (typically within 6-12 h of surgery) unless haemostasis has not been successfully achieved.
